Diphencyprone

Diphencyprone

SCHEMBL105663

O=c1c(-c2ccccc2)c1-c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 1.00
MAPT P10636 2/20 1.00
LMNA P02545 1/20 1.00
ALDH1A1 P00352 3/20 0.50
HDAC4 P56524 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
GAA P10253 2/20 0.43
CFTR P13569 1/20 0.43
GOPC Q9HD26 1/20 0.43
KDM4E B2RXH2 1/20 0.43
PLA2G10 O15496 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
TYMP P19971 3/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18392174 0.93 HTT (0.88) HTTMAPTLMNAALDH1A1HDAC4
SCHEMBL26201011 0.84 LMNA (0.71) HTTMAPTLMNAALDH1A1HDAC4
SCHEMBL19397826 0.83 MAPT (0.68) HTTMAPTLMNAALDH1A1HPGD
Diphencyprone SCHEMBL11320515 0.83 LMNA (0.68) HTTMAPTLMNAALDH1A1HPGD
SCHEMBL24625400 0.79 MAPT (0.65) HTTMAPTLMNAALDH1A1HPGD
SCHEMBL12432444 0.79 MAPT (0.65) HTTMAPTLMNAALDH1A1HDAC4
SCHEMBL24625466 0.79 HTT (0.65) HTTMAPTLMNAALDH1A1HDAC4
SCHEMBL10967156 0.79 LMNA (0.62) HTTMAPTLMNAALDH1A1HDAC4
SCHEMBL216526 0.78 ALDH1A1 (0.67) HTTMAPTLMNAALDH1A1HPGD
SCHEMBL11585918 0.77 LMNA (0.61) HTTMAPTLMNACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1616 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138973-A1 SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE SITRYX THERAPEUTICS LTD (GB) 2026-05-21 US claimed
US-20260137680-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LTD (GB) 2026-05-21 US claimed
US-20260085061-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2026-03-26 US claimed
EP-4634167-A1 SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE Sitryx Therapeutics Limited (GB) 2025-10-22 EP claimed
EP-4612132-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS Sitryx Therapeutics Limited (GB) 2025-09-10 EP claimed
CN-119930671-A 1-Indenone derivative, preparation method and application thereof 西华大学 2025-05-06 CN claimed
EP-4543875-A1 OXADIAZOLE DERIVATIVES, PREPARATION PROCESS THEREOF AND THEIR USE IN TREATING INFLAMMATORY DISEASES Sitryx Therapeutics Limited (GB) 2025-04-30 EP claimed
US-20250127746-A1 TOPICAL CONTACT SENSITIZERS TO TREAT CANCER SQUAREX PHARMACEUTICAL CORP (US) 2025-04-24 US claimed
EP-4536236-A2 METHODS OF MODULATING ATXN2 EXPRESSION University of Utah Research Foundation (US) 2025-04-16 EP claimed
WO-2025064646-A1 COMPOSITIONS AND METHODS FOR WOUND HEALING AND HAIR GROWTH USING POLYELECTROLYTE COMPLEX (PEC) FILMS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2025-03-27 WO claimed
US-6117223-A Hot melt inks containing polyketones XEROX CORPORATION (US) 2000-09-12 US claimed
US-6063399-A BLEND OF (METH)ACRYLATE COPOLYMER AND PLASTICIZER ROEHM GMBH CHEMISCHE FABRIK (DE) 2000-05-16 US claimed
US-5846559-A Skin patch for use in contact immunotherapy HOPP ROBERT B (US) 1998-12-08 US claimed
US-5663030-A A PHENYL OR NORBORNANE DERIVATIVE AS AN ADDITIVE TO REDUCE HEAT AND ENERGY REQUIRED TO FUSE THE TONER AND TO REDUCE JAMMING OF THE EQUIPMENT XEROX CORPORATION (US) 1997-09-02 US claimed
WO-1996032142-A1 SKIN PATCH FOR USE IN CONTACT IMMUNOTHERAPY HOPP ROBERT B (US) 1996-10-17 WO claimed
US-4985464-A Drug compositions for local treatment of alopecia areata HAPPLE RUDOLF (DE) 1991-01-15 US claimed
EP-0062157-B1 MEDICINAL PREPARATION FOR THE LOCAL TREATMENT OF ALOPECIA AREATA Happle, Rudolf, Prof. Dr.med. (DE) 1984-06-27 EP claimed
EP-0062157-A1 Medicinal preparation for the local treatment of alopecia areata Happle, Rudolf, Prof. Dr.med. (DE) 1982-10-13 EP claimed
US-4199021-A Thermal energy storage apparatus JOHNSON CONTROLS, INC. (US) 1980-04-22 US claimed
US-4128422-A Cyclopropenone vesicular imaging composition, element and process EASTMAN KODAK COMPANY (US) 1978-12-05 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085061-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS PDK1, PDK2, PDK4 HTT 4159/4885MAPT 3687/4885LMNA 2450/4885
US-20260137680-A1 NOVEL COMPOUNDS CCR1, CCR4, CCR3 HTT 2556/4885MAPT 4412/4885LMNA 2211/4885
US-20260138973-A1 SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE CCR1, CCR2, CBR1 HTT 3453/4885MAPT 4800/4885LMNA 2789/4885
US-20250127746-A1 TOPICAL CONTACT SENSITIZERS TO TREAT CANCER DECR2, DECR1, CYSLTR2 HTT 4691/4885MAPT 3989/4885LMNA 4065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.